Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

fresenius kabi brasil ltda - cloreto de zinco, cloreto fÉrrico, fluoreto de sÓdio, cloreto cÚprico, dicloreto de manganês tetraidratado, selenito de sÓdio, iodeto de potÁssio, cloreto crÔmico hexaidratado, molibdato de sódio diidratado - nutrientes parenterais

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

chemicaltech importaÇÃo, exportaÇÃo e comÉrcio de produtos mÉdicos, farmacÊuticos e hospitalares ltda - cloridrato de palonosetrona - antiemeticos e antinauseantes

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

chemicaltech importaÇÃo, exportaÇÃo e comÉrcio de produtos mÉdicos, farmacÊuticos e hospitalares ltda - sulfato de vincristina - antineoplasico

União Europeia - português - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. o uso desta vacina deve ser de acordo com as recomendações oficiais.

União Europeia - português - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

upsa sas - paracetamol - comprimido orodispersível - 500 mg - paracetamol 500 mg - paracetamol - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

upsa sas - paracetamol - comprimido orodispersível - 500 mg - paracetamol 500 mg - paracetamol - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - paracetamol - comprimido - 500 mg - paracetamol 500 mg - paracetamol - genérico - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - paracetamol - comprimido - 500 mg - paracetamol 500 mg - paracetamol - genérico - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

upsa sas - paracetamol - comprimido orodispersível - 500 mg - paracetamol 500 mg - paracetamol - n/a - duração do tratamento: curta ou média duração